A method and device for treating a mammalian organism to obtain a desired local or systemic physiological or pharmacological effect is provided. The method includes administering a sustained release drug delivery system to a mammalian organism in need of such treatment at an area wherein release of an effective agent is desired and allowing the effective agent to pass through the device in a controlled manner. The device includes an inner core or reservoir including the effective agent, an impermeable tube which encloses portions of the reservoir, and a permeable member at an end of the tube.

A probiotic-encapsulating gum Arabic (GA) composite fiber/capsule, including: lactic acid bacteria and an electrospun fiber or electrosprayed capsule, where the lactic acid bacteria are encapsulated in the electrospun fiber or electrosprayed capsule by electro-hydro dynamics (EHD) technology. The electrospun fiber or electrosprayed capsule is prepared by compounding a polymer matrix with GA, and the polymer matrix is polyvinyl alcohol (PVOH), polyvinylpyrrolidone (PVP), whey protein concentrate (WPC) or maltodextrin (MD). A preparation method and an application of the composite fiber/capsule are also provided.

Functionalized single walled or multi-walled carbon nanotubes (f-CNTs) can be delivered into mammals to targeted organs, such as the kidney and the liver. These f-CNTs may be non-covalently linked or covalently linked to therapeutic agents. In particular, the application delivers carbon nanotube-therapeutic agent conjugates to a target organ, thereby preventing or reducing damages to the organ caused by other agents or procedure.

Membranes are described that may include aligned carbon nanotubes coated with an inorganic support layer and a polymeric matrix. Methods of membrane fabrication are described that may include coating an aligned carbon nanotube array with an inorganic support layer followed by infiltration with a polymeric solvent or solution. The support carbon nanotube membrane may have improved performance for separations such as desalination, drug delivery, or pharmaceuticals.

Provided is a composite nanoparticle in which an immunogenic plasma protein is coated on the surface of the nanoparticle due to the enhanced immune activity function caused by structural changes in immunogenic protein coronas.

A reservoir device comprising an active agent formulation contained within a reservoir is described. The active agent formulation comprises more than one active agent. The reservoir is defined by a biodegradable, permeable polymer membrane. The membrane allows for diffusion of the more than one active agent of the formulation there through when positioned subcutaneously in a body of a subject.

Drug delivery devices and methods are provided for administering gemcitabine to a patient in need of treatment of bladder cancer by intravesically administering gemcitabine into the bladder of the patient to achieve a sustained concentration of the gemcitabine in urine in the bladder sufficient to produce a therapeutically effective concentration of the gemcitabine in the tissues of the bladder. In embodiments, the local administration into the patient's bladder is at a mean average amount of from 1 mg/day to about 300 mg/day of the gemcitabine (FBE).

This application relates to compositions comprising shortened fibers of poly-N-acetylglucosamine and/or a derivative thereof (“sNAG nanofibers”) and the use of such compositions in the treatment of disease.

Provided herein is a nanopore structure, which in one aspect is a “carbon nanotube porin”, that comprises a short nanotube with an associated lipid coating. Also disclosed are compositions and methods enabling the preparation of such nanotube/lipid complexes. Further disclosed is a method for therapeutics delivery that involves a drug delivery agent comprising a liposome with a NT loaded with a therapeutic agent, introducing the therapeutic agent into a cell or a tissue or an organism; and subsequent release of the therapeutic agents into a cell.

An adsorption method adsorbs a substance by using a tube-shaped apatite crystal. The apatite crystal may be a monocrystal given by a general formula M.sup.2.sub.5(PO.sub.4).sub.3X (M.sup.2 denotes at least one element selected from the group consisting of divalent alkali earth metal and Eu, and X denotes at least one element or molecule selected from the group consisting of halogen element and OH). The outer form of the apatite crystal may be a hexagonal prism in which the aperture of a hole formed on a top surface or bottom surface of the hexagonal prism may be hexagonal.